Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.

Reema R ModyKellie L MeyerJennifer M WardKen B O'Day

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)

Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) that may offer the potential to achieve stringent glycemic goals, weight loss targets, and composite treatment goals at a lower cost per responder compared to semaglutide 1 mg among people with T2D.

Keyphrases

weight loss
type diabetes
bariatric surgery
rheumatoid arthritis
public health
risk assessment
global health
climate change
skeletal muscle
systemic sclerosis
disease activity
idiopathic pulmonary fibrosis
smoking cessation
obese patients